1. Home
  2. MGRX vs ACXP Comparison

MGRX vs ACXP Comparison

Compare MGRX & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mangoceuticals Inc.

MGRX

Mangoceuticals Inc.

HOLD

Current Price

$0.41

Market Cap

7.1M

Sector

Technology

ML Signal

HOLD

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

HOLD

Current Price

$1.43

Market Cap

6.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGRX
ACXP
Founded
2021
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
6.2M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
MGRX
ACXP
Price
$0.41
$1.43
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$95.50
AVG Volume (30 Days)
1.1M
179.1K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
55.17
N/A
EPS
N/A
N/A
Revenue
$456,021.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$1.31
52 Week High
$2.75
$8.34

Technical Indicators

Market Signals
Indicator
MGRX
ACXP
Relative Strength Index (RSI) 47.52 47.60
Support Level $0.34 $1.33
Resistance Level $0.47 $1.75
Average True Range (ATR) 0.04 0.06
MACD -0.00 0.00
Stochastic Oscillator 49.40 37.50

Price Performance

Historical Comparison
MGRX
ACXP

About MGRX Mangoceuticals Inc.

Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Share on Social Networks: